KRAS and cholangiocarcinoma: Among these, scRNA-seq data confirmed that SLC22A3 (OCT3) is specifically expressed in cholangiocytes within human CCA tumors (Figs. 8D and S16A), regardless of their underlying mutation status (IDH1, KRAS, TP53, or wild-type) (Figs. 8E and S16B) or anatomical origin (Figs. 8F,G and S16C,D).